Epilepsy in women of childbearing age
If anticonvulsants cannot be avoided use carbamazepine
Mothers who have epilepsy inevitably worry about the effect of the disease on their unborn babies. Questions about the impact of seizures on maternal and fetal health arise long before pregnancy occurs, and there is an increasing awareness of the teratogenic effect of anticonvulsant drugs. There is a genuine dilemma between controlling seizures and protecting the fetus from unnecessary exposure to anticonvulsant drugs.' Unfortunately, some women are not told about the risk to the fetus and are not offered prenatal diagnosis. 2 About one in 200 pregnancies is in a woman with epilepsy.3 Received wisdom suggests that pregnancy causes an increase in the fits,4'5 but this increase is largely caused by women not taking their drugs, losing sleep, and being given inadequate treatment. 6 The pregnancy itself may have little influence on the pattern of attacks, and in a recent study there was no difference in the frequency of seizures before and during pregnancy.7 In general, women whose epilepsy is well controlled have few problems from their disease in pregnancy, and seizures increase in those whose attacks are poorly controlled at other times. In these circumstances generalised seizures are more hazardous than minor attacks: stillbirths have been recorded after a single generalised convulsion,8 and in a series ofmothers with status epilepticus nine mothers and 14 infants died.9 Most of the complications of pregnancy are increased when the epilepsy is poorly controlled.9'0 Plasma concentrations of anticonvulsant drugs decrease during pregnancy. This does not commonly cause an increase in seizures, but when attacks do increase the plasma concentrations of the drugs are usually low.7 Reduction in blood concentration of anticonvulsant drugs may result from poor compliance,6 increased metabolism of the drugs by hepatic enzymes," and a progressive reduction in albumin concentration, which may be associated with increased clearance of the unbound drug. '2 Many different congenital malformations have been reported in children of epileptic mothers, and all anticonvulsant drugs have been incriminated as possible causes of the malformations. The most common abnormalities are orofacial clefts and congenital heart disease.'3 Seventy abnormalities occur in every 1000 births to epileptic mothers, 2-4 times the rate in the general population. Abnormalities are more likely if anticonvulsant drugs are prescribed,'3 if high concentrations of them are used,' and if more than one is used.'" The first indication of a'specific teratogenic effect resulting from anticonvulsant treatment was in 1982, when it was reported that nine out of 72 infants with neural tube defects in the Rhone Alps region of France had been exposed to valproic acid.'6 A subsequent review of 2111 pregnancies showed a 1% risk of neural tube defects in infants exposed to valproic acid in utero'7-20 times the rate in the general population.
Oakeshott and Hunt have recently reported three cases of spina bifida in infants born to women taking sodium valproate, none of whom were aware of the risk and none of whom were offered prenatal diagnosis.2 Their report emphasised the need for adequate couns'elling ofpregnant women about the risks of anticonvulsant drugs, but ofequal importance are the original choice of drug for girls with epilepsy, avoidance of polypharmacy, and regular review of the need for drug treatment. Although no anticonvulsant drug is free of risk, it seems prudent to avoid prescribing sodium valproate to girls unless there are specific indications such as generalised epilepsy with a combination of petit mal and major seizures. Petit mal alone is seldom a problem by the time pregnancy occurs, and thus even in the generalised epilepsies regular review is needed of the specific need for valproate.
The present consensus is that carbamazepine alone should be the first choice for a girl who requires an anticonvulsant drug. The need for continued treatment should then be reviewed after two years' remission. The results of the Medical Research Council's anticonvulsant withdrawal trial should provide more accurate information on relapse rates in the various groups, but in general any young woman free of seizures for two years should be offered the choice of withdrawing from anticonvulsant treatment.
There is much scope for improving the management of epilepsy in women of childbearing age. The greatest needs are better education of the women and their doctors and the recognition that in this particular group long term planning and good communication among the various caring agencies are of the utmost importance. MICHAEL 
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